Cathepsin S Causes Inflammatory Pain via Biased Agonism of PAR2 and TRPV4*

Background: Proteases trigger inflammation and pain by cleaving protease-activated receptors (PARs) at defined sites. Results: Cathepsin S (Cat-S) cleaved PAR2 at a unique site E56↓T57, leading to Gαs-mediated cAMP accumulation and TRPV4-dependent inflammation and pain. Conclusion: Cat-S is a biased agonist of PAR2- and TRPV4-dependent inflammation and pain. Significance: PARs integrate responses to diverse proteases. Serine proteases such as trypsin and mast cell tryptase cleave protease-activated receptor-2 (PAR2) at R36↓S37 and reveal a tethered ligand that excites nociceptors, causing neurogenic inflammation and pain. Whether proteases that cleave PAR2 at distinct sites are biased agonists that also induce inflammation and pain is unexplored. Cathepsin S (Cat-S) is a lysosomal cysteine protease of antigen-presenting cells that is secreted during inflammation and which retains activity at extracellular pH. We observed that Cat-S cleaved PAR2 at E56↓T57, which removed the canonical tethered ligand and prevented trypsin activation. In HEK and KNRK cell lines and in nociceptive neurons of mouse dorsal root ganglia, Cat-S and a decapeptide mimicking the Cat-S-revealed tethered ligand-stimulated PAR2 coupling to Gαs and formation of cAMP. In contrast to trypsin, Cat-S did not mobilize intracellular Ca2+, activate ERK1/2, recruit β-arrestins, or induce PAR2 endocytosis. Cat-S caused PAR2-dependent activation of transient receptor potential vanilloid 4 (TRPV4) in Xenopus laevis oocytes, HEK cells and nociceptive neurons, and stimulated neuronal hyperexcitability by adenylyl cyclase and protein kinase A-dependent mechanisms. Intraplantar injection of Cat-S caused inflammation and hyperalgesia in mice that was attenuated by PAR2 or TRPV4 deletion and adenylyl cyclase inhibition. Cat-S and PAR2 antagonists suppressed formalin-induced inflammation and pain, which implicates endogenous Cat-S and PAR2 in inflammatory pain. Our results identify Cat-S as a biased agonist of PAR2 that causes PAR2- and TRPV4-dependent inflammation and pain. They expand the role of PAR2 as a mediator of protease-driven inflammatory pain.

[1]  T. Yaksh,et al.  Quantitative assessment of tactile allodynia in the rat paw , 1994, Journal of Neuroscience Methods.

[2]  R. Mullins,et al.  β-Arrestin–Dependent Endocytosis of Proteinase-Activated Receptor 2 Is Required for Intracellular Targeting of Activated Erk1/2 , 2000, The Journal of cell biology.

[3]  L. Devi,et al.  Inflammatory Mediators Regulate Cathepsin S in Macrophages and Microglia: A Role in Attenuating Heparan Sulfate Interactions , 1999, Molecular medicine.

[4]  O. Sasso,et al.  Cathepsin S release from primary cultured microglia is regulated by the P2X7 receptor , 2010, Glia.

[5]  S. Bevan,et al.  Inhibition of spinal microglial cathepsin S for the reversal of neuropathic pain , 2007, Proceedings of the National Academy of Sciences.

[6]  S. Coughlin,et al.  Tissue factor- and factor X-dependent activation of protease-activated receptor 2 by factor VIIa. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[7]  G. Cottrell,et al.  Trypsin IV, a Novel Agonist of Protease-activated Receptors 2 and 4* , 2004, Journal of Biological Chemistry.

[8]  Arthur Christopoulos,et al.  Signalling bias in new drug discovery: detection, quantification and therapeutic impact , 2012, Nature Reviews Drug Discovery.

[9]  D. Bernstein,et al.  Delayed Onset of Inflammation in Protease-Activated Receptor-2-Deficient Mice1 , 2000, The Journal of Immunology.

[10]  J. Friedman,et al.  Abnormal osmotic regulation in trpv4-/- mice , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[11]  Ligong Liu,et al.  An antagonist of human protease activated receptor‐2 attenuates PAR2 signaling, macrophage activation, mast cell degranulation, and collagen‐induced arthritis in rats , 2012, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[12]  M. Malcangio,et al.  The Liberation of Fractalkine in the Dorsal Horn Requires Microglial Cathepsin S , 2009, The Journal of Neuroscience.

[13]  H. Samaratunga,et al.  Kallikrein-related Peptidase 4 (KLK4) Initiates Intracellular Signaling via Protease-activated Receptors (PARs) , 2008, Journal of Biological Chemistry.

[14]  E. Diamandis,et al.  Proteinase-activated Receptors, Targets for Kallikrein Signaling* , 2006, Journal of Biological Chemistry.

[15]  O. Schilling,et al.  Proteomic identification of protease cleavage sites characterizes prime and non-prime specificity of cysteine cathepsins B, L, and S. , 2011, Journal of proteome research.

[16]  J. d'Alayer,et al.  Pseudomonas aeruginosa elastase disables proteinase-activated receptor 2 in respiratory epithelial cells. , 2005, American journal of respiratory cell and molecular biology.

[17]  Yi Dai,et al.  Sensitization of TRPA1 by PAR2 contributes to the sensation of inflammatory pain. , 2007, The Journal of clinical investigation.

[18]  M. Steinhoff,et al.  Role for protease activity in visceral pain in irritable bowel syndrome. , 2007, The Journal of clinical investigation.

[19]  C. Wahlestedt,et al.  Molecular cloning of a potential proteinase activated receptor. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[20]  M. Hollenberg,et al.  Trypsin IV or Mesotrypsin and p23 Cleave Protease-activated Receptors 1 and 2 to Induce Inflammation and Hyperalgesia* , 2007, Journal of Biological Chemistry.

[21]  N. Lambert,et al.  The Bile Acid Receptor TGR5 Does Not Interact with β-Arrestins or Traffic to Endosomes but Transmits Sustained Signals from Plasma Membrane Rafts* , 2013, The Journal of Biological Chemistry.

[22]  J. Pin,et al.  Interaction of Protease-Activated Receptor 2 with G Proteins and β-Arrestin 1 Studied by Bioluminescence Resonance Energy Transfer , 2013, Front. Endocrinol..

[23]  N. Bunnett,et al.  Proteolytic activation of the epithelial sodium channel (ENaC) by the cysteine protease cathepsin-S , 2012, Pflügers Archiv - European Journal of Physiology.

[24]  N. Bunnett,et al.  Trafficking of Proteinase-activated Receptor-2 and β-Arrestin-1 Tagged with Green Fluorescent Protein , 1999, The Journal of Biological Chemistry.

[25]  J. Wallace,et al.  Agonists of proteinase-activated receptor 2 induce inflammation by a neurogenic mechanism , 2000, Nature Medicine.

[26]  Jennifer L. Harris,et al.  Cellular Localization of Membrane-type Serine Protease 1 and Identification of Protease-activated Receptor-2 and Single-chain Urokinase-type Plasminogen Activator as Substrates* , 2000, The Journal of Biological Chemistry.

[27]  J. Madon,et al.  Protease‐activated receptor‐1 cleaved at R46 mediates cytoprotective effects , 2012, Journal of thrombosis and haemostasis : JTH.

[28]  J. Griffin,et al.  Biased agonism of protease-activated receptor 1 by activated protein C caused by noncanonical cleavage at Arg46. , 2012, Blood.

[29]  J. Wallace,et al.  A major role for proteolytic activity and proteinase-activated receptor-2 in the pathogenesis of infectious colitis. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[30]  S. Bevan,et al.  Role of the cysteine protease cathepsin S in neuropathic hyperalgesia , 2007, PAIN.

[31]  W. Krajewska,et al.  Transient Receptor Potential Vanilloid 4 blockade protects against experimental colitis in mice: a new strategy for inflammatory bowel diseases treatment? , 2012, Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society.

[32]  P. McNaughton,et al.  Activation of the TRPV4 Ion Channel Is Enhanced by Phosphorylation , 2009, The Journal of Biological Chemistry.

[33]  A. Kuliopulos,et al.  Matrix metalloproteases and PAR1 activation. , 2011, Blood.

[34]  Roy Jones,et al.  Evidence for the activation of PAR‐2 by the sperm protease, acrosin: expression of the receptor on oocytes , 2000, FEBS letters.

[35]  M. Hollenberg,et al.  Neutrophil Elastase and Proteinase-3 Trigger G Protein-biased Signaling through Proteinase-activated Receptor-1 (PAR1)* , 2013, The Journal of Biological Chemistry.

[36]  M. Hollenberg,et al.  Proteinase-activated receptor-2 and human lung epithelial cells: disarming by neutrophil serine proteinases. , 2003, American journal of respiratory cell and molecular biology.

[37]  M. Dalrymple,et al.  Enhanced BRET Technology for the Monitoring of Agonist-Induced and Agonist-Independent Interactions between GPCRs and β-Arrestins , 2011, Front. Endocrin..

[38]  D. Payan,et al.  Mast cell tryptase regulates rat colonic myocytes through proteinase-activated receptor 2. , 1997, The Journal of clinical investigation.

[39]  V. Trivedi,et al.  Platelet Matrix Metalloprotease-1 Mediates Thrombogenesis by Activating PAR1 at a Cryptic Ligand Site , 2009, Cell.

[40]  J. Hoxie,et al.  Interactions of Mast Cell Tryptase with Thrombin Receptors and PAR-2* , 1997, The Journal of Biological Chemistry.

[41]  D. Cohen,et al.  Transient receptor potential vanilloid 4 mediates protease activated receptor 2-induced sensitization of colonic afferent nerves and visceral hyperalgesia. , 2008, American journal of physiology. Gastrointestinal and liver physiology.

[42]  A. Zijlstra,et al.  The membrane-anchored serine protease, TMPRSS2, activates PAR-2 in prostate cancer cells. , 2005, The Biochemical journal.

[43]  Francesco Leonetti,et al.  Substrate Profiling of Cysteine Proteases Using a Combinatorial Peptide Library Identifies Functionally Unique Specificities* , 2006, Journal of Biological Chemistry.

[44]  M. Malcangio,et al.  Microglial signalling mechanisms: Cathepsin S and Fractalkine , 2012, Experimental Neurology.

[45]  A. Basbaum,et al.  Proteinase-activated receptor-2 and hyperalgesia: A novel pain pathway , 2001, Nature Medicine.

[46]  M. Steinhoff,et al.  Proteinase‐activated receptor‐2 in human skin: tissue distribution and activation of keratinocytes by mast cell tryptase , 1999, Experimental dermatology.

[47]  D. Payan,et al.  Mechanisms of Desensitization and Resensitization of Proteinase-activated Receptor-2* , 1996, The Journal of Biological Chemistry.

[48]  N. Bunnett,et al.  Protease-activated receptors: contribution to physiology and disease. , 2004, Physiological reviews.

[49]  S. Coughlin,et al.  Molecular cloning, expression and potential functions of the human proteinase-activated receptor-2. , 1996, The Biochemical journal.

[50]  J. Levine,et al.  Protease‐activated receptor 2 sensitizes the transient receptor potential vanilloid 4 ion channel to cause mechanical hyperalgesia in mice , 2007, The Journal of physiology.

[51]  Silvia Amadesi,et al.  Protease-activated Receptor 2 (PAR2) Protein and Transient Receptor Potential Vanilloid 4 (TRPV4) Protein Coupling Is Required for Sustained Inflammatory Signaling* , 2013, The Journal of Biological Chemistry.

[52]  M. Hollenberg,et al.  2-Furoyl-LIGRLO-amide: A Potent and Selective Proteinase-Activated Receptor 2 Agonist , 2004, Journal of Pharmacology and Experimental Therapeutics.

[53]  E. Mayer,et al.  Protease-Activated Receptor 2 Sensitizes the Capsaicin Receptor Transient Receptor Potential Vanilloid Receptor 1 to Induce Hyperalgesia , 2004, The Journal of Neuroscience.

[54]  E. Lerner,et al.  Cathepsin S Signals via PAR2 and Generates a Novel Tethered Ligand Receptor Agonist , 2014, PloS one.

[55]  Michel Bouvier,et al.  Real-time monitoring of receptor and G-protein interactions in living cells , 2005, Nature Methods.

[56]  M. Hollenberg,et al.  Neutrophil Elastase Acts as a Biased Agonist for Proteinase-activated Receptor-2 (PAR2)* , 2011, The Journal of Biological Chemistry.

[57]  M. Bogyo,et al.  Cathepsin S is activated during colitis and causes visceral hyperalgesia by a PAR2-dependent mechanism in mice. , 2011, Gastroenterology.

[58]  S. Coughlin,et al.  Agonist Recognition by Proteinase-activated Receptor 2 and Thrombin Receptor , 1996, The Journal of Biological Chemistry.

[59]  A. Denadai-Souza,et al.  Role of transient receptor potential vanilloid 4 in rat joint inflammation. , 2012, Arthritis and rheumatism.

[60]  V. Turk,et al.  Expression and activity profiling of selected cysteine cathepsins and matrix metalloproteinases in synovial fluids from patients with rheumatoid arthritis and osteoarthritis , 2010, Biological chemistry.

[61]  F. Cattaruzza,et al.  A role for transient receptor potential vanilloid 4 in tonicity‐induced neurogenic inflammation , 2010, British journal of pharmacology.

[62]  H. Samaratunga,et al.  Prostatic trypsin-like kallikrein-related peptidases (KLKs) and other prostate-expressed tryptic proteinases as regulators of signalling via proteinase-activated receptors (PARs) , 2008, Biological chemistry.

[63]  J Y Suen,et al.  Modulating human proteinase activated receptor 2 with a novel antagonist (GB88) and agonist (GB110) , 2012, British journal of pharmacology.

[64]  A. Agarwal,et al.  PAR1 Is a Matrix Metalloprotease-1 Receptor that Promotes Invasion and Tumorigenesis of Breast Cancer Cells , 2005, Cell.

[65]  G. Mize,et al.  Prostate-Specific Kallikreins-2 and -4 Enhance the Proliferation of DU-145 Prostate Cancer Cells through Protease-Activated Receptors-1 and -2 , 2008, Molecular Cancer Research.